PharmaShots | Incisive News in 3 Shots

Subscribe Now

high AFP

Eli Lilly's Cyramza (ramucirumab) Receives FDA's Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carcinoma

Eli Lilly's Cyramza (ramucirumab) Receives FDA's Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carc...

May 13, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us